Discover
EVO
Evotec SE
2.85
2 x 2.07
2 x 3.63
bid
ask
+
0.05
1.79%
2 @ 05:34 AM
2.87 +0.02 (0.70%)
| Ytd | -7.47% | |
| 1y | -32.46% |
2.84
day range
2.90
2.31
52 week range
4.42
| Open | 2.89 | Prev Close | 2.80 | Low | 2.84 | High | 2.90 | Mkt Cap | 1.01B |
| Vol | 35.48K | Avg Vol | 71.10K | EPS | -0.62 | P/E | N/A | Forward P/E | -14.29 |
| Beta | 1.30 | Short Ratio | 0.71 | Inst. Own | 2.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 2.90 | 200-d Avg | 3.21 | 1yr Est | 5.23 |
EVO News
seekingalpha.com
Evommune's Healthy Balance Sheet Buys Them Time For AD
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre
gurufocus.com
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics P
prnewswire.com
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary co
businesswire.com
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontan
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu